Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
387 questions in 55 reviews · Common Mental Disorders
current versionsNo studies 387 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Lithium vs zuclopenthixol Adverse events · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs risperidone Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs aripiprazole Efficacy: response (categorical) BMRS change ≥ 50% from baseline to end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs topiramate Efficacy: response (continuous) YMRS change by ≥ 50% at end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs clonazepam Efficacy: response (categorical) YMRS change ≥ 50% from baseline to end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs clonazepam Efficacy : remission (categorical) YMRS ≤ 12 at end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs clonazepam Acceptability: total withdrawals · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs clonazepam Adverse events · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs electroconvulsive therapy (ECT) Efficacy: response (categorical) YMRS change ≥ 50% from baseline to end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs electroconvulsive therapy (ECT) Efficacy: remission (categorical) YMRS ≤ 12 at end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs electroconvulsive therapy (ECT) Acceptability: total withdrawals · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs electroconvulsive therapy (ECT) Adverse events · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs all antimanic agents Efficacy: remission (categorical) YMRS ≤ 12 at end of study · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Lithium vs all antimanic agents Adverse events · acute mania Lithium for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Valproate vs lithium Number of participants with any adverse event (primary tolerability outcome) · Children and adolescents with acute mania Valproate for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Valproate vs olanzapine Number of participants with any adverse event (primary tolerability outcome) · Adults (aged 18 and over) with acute mania Valproate for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Valproate vs risperidone Number of participants with any adverse event (primary tolerability outcome) · Children and adolescents with acute mania Valproate for acute mania (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (fluoxetine 20 mg/d) with mianserin (60 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d) with placebo Quality of life ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs augmentation of current antidepressant (SSRI) with placebo Response to treatment ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs augmentation of current antidepressant (SSRI) with placebo Remission ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (SSRI) with busiprone (20 mg/d to 60 mg/d) vs augmentation of current antidepressant (SSRI) with placebo Quality of life ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (various) with cariprazine (1 mg/d to 4.5 mg/d) vs augmentation of current antidepressant (various) with placebo Quality of life ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo Remission ‐ not reported · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with olanzapine (5 mg/d to 20 mg/d) vs augmentation of current antidepressant (fluoxetine 20 mg/d to 60 mg/d) with placebo Quality of life ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Augmentation of current antidepressant (SSRI) with ziprasidone (40 mg/d to 160 mg/d) vs augmentation of current antidepressant (SSRI) with placebo or continue on SSRI monotherapy Quality of life ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Switching to mianserin (60 mg/d) vs continuing on current antidepressant (fluoxetine 20 mg/d) Quality of life ‐ not measured · treatment‐resistant depression in adults Pharmacological interventions for treatment‐resistant depression in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Stand‐alone couple or family therapy vs other structured or non‐specific intervention Instances of severe aggression · post‐traumatic stress disorder (PTSD) Couple and family therapies for post‐traumatic stress disorder (PTSD) (2019) · Cochrane | no estimate extracted | NR | No studies |
Stand‐alone couple or family therapy vs no treatment Instances of severe aggression · post‐traumatic stress disorder (PTSD) Couple and family therapies for post‐traumatic stress disorder (PTSD) (2019) · Cochrane | no estimate extracted | NR | No studies |
Agomelatine vs placebo Quality of life · adults with a history of SAD Melatonin and agomelatine for preventing seasonal affective disorder (2019) · Cochrane | no estimate extracted | NR | No studies |
Agomelatine vs placebo Quality of interpersonal and social functioning · adults with a history of SAD Melatonin and agomelatine for preventing seasonal affective disorder (2019) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs medication Quality of life (physical) · clinical diagnosis of depression Acupuncture for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs medication Quality of life (emotional) · clinical diagnosis of depression Acupuncture for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs psychological therapy Quality of life (physical) · clinical diagnosis of depression Acupuncture for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs psychological therapy Quality of life (emotional) · clinical diagnosis of depression Acupuncture for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs no treatment/wait list/treatment Quality of life (physical) · clinical diagnosis of depression Acupuncture for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Acupuncture vs no treatment/wait list/treatment Quality of life (emotional) · clinical diagnosis of depression Acupuncture for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Dropouts · heterosexual adult couples aged > 18 with a partner having a clinical diagnosis of depressive disorder Couple therapy for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Persistence of depression at the end of treatment · heterosexual adult couples aged > 18 with a partner having a clinical diagnosis of depressive disorder Couple therapy for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Persistence of depression at end of treatment · heterosexual adult couples aged >18 with a partner having a clinical diagnosis of depressive disorder Couple therapy for depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall maternal satisfaction (17 weeks) · women with a history of postnatal depression Antidepressants for preventing postnatal depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in the maternal relationship with the baby (17 weeks) · women with a history of postnatal depression Antidepressants for preventing postnatal depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Establishment or continuation of breastfeeding (17 weeks) · women with a history of postnatal depression Antidepressants for preventing postnatal depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall maternal satisfaction (17 weeks) · women with a history of postnatal depression Antidepressants for preventing postnatal depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Improvement in the maternal relationship with the baby (17 weeks) · women with a history of postnatal depression Antidepressants for preventing postnatal depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Establishment or continuation of breastfeeding (17 weeks) · women with a history of postnatal depression Antidepressants for preventing postnatal depression (2018) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs placebo Outcomes (2‐6 months post‐treatment) · adults with panic disorder Antidepressants versus placebo for panic disorder in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
Selective serotonin reuptake inhibitors vs placebo Outcomes (2‐6 months post‐treatment) · adults with panic disorder Antidepressants versus placebo for panic disorder in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
Serotonin‐norepinephrine reuptake inhibitors vs placebo Outcomes (2‐6 months post‐treatment) · adults with panic disorder Antidepressants versus placebo for panic disorder in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
Tricyclic antidepressants vs placebo Outcomes (2‐6 months post‐treatment) · adults with panic disorder Antidepressants versus placebo for panic disorder in adults (2018) · Cochrane | no estimate extracted | NR | No studies |
Client feedback vs no client feedback Clients' psychosocial functioning · children and adolescents, 11 to 18 years old, with mental health problems Client feedback in psychological therapy for children and adolescents with mental health problems (2018) · Cochrane | no estimate extracted | NR | No studies |